The Research Animal Support Facility (RASF) has been a shared resource since the original Cancer Center Support Grant (CCSG) was awarded in 1975. The University of Texas M.D. Anderson Cancer Center has supported the RASF over these years, using institutional funds for the acquisition of major operational equipment and for remodeling and utility upgrades. The RASF has two distinct sites. One is within the perimeter of the Texas Medical Center, and the other is approximately 1 mile south of the Texas Medical Center at the Smith Research Building. Both animal facilities are accredited by the Association for Assessment and Accreditation of Laboratory Animal Core International, have an approved Animal Welfare Assurance Form (A3343-01), and are part of a research facility registered with the United States Department of Agriculture (74-R-065). The RASF is composed of three specific-pathogen-free (SPF) general rodent barriers, an SPF transgenic mouse barrier, a biohazard-use facility, conventional rodent housing, large-animal housing (for monkeys, dogs, pigs, and rabbits) and quarantine facilities. The RASF maintains approximately 37,000 animals daily; 98% are rodents, most of which are mice. The remaining 2% are monkeys, dogs, pigs, rabbits, guinea pigs, hamsters, and frogs. Also used are sea urchins and fruit flies. Animals are used to answer questions about how to diagnose, treat, and prevent cancer and to understand its causes. Investigators in all 13 research departments and in 24 of 29 clinical departments are supported by the RASF. In addition, clinical, surgical, diagnostic imaging,, and irradiation facilities and services are provided, as are diagnostic and pathology laboratory facilities and services. Specific SPF facilities for severe combined immuno-deficiency (SCID) mice use are also provided, and new, expanded SPF facilities for knockout and transgenic mice production and use are being developed, with occupancy expected in about April, 1998.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-24
Application #
6101815
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
24
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Yu, Wangie; Chen, Yunyun; Dubrulle, Julien et al. (2018) Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep 8:4306
Tanco, Kimberson; Azhar, Ahsan; Rhondali, Wadih et al. (2018) The Effect of Message Content and Clinical Outcome on Patients' Perception of Physician Compassion: A Randomized Controlled Trial. Oncologist 23:375-382
Elimova, Elena; Wang, Xuemei; Qiao, Wei et al. (2018) Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94:345-353
Hoadley, Katherine A; Yau, Christina; Hinoue, Toshinori et al. (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291-304.e6
Ma, Jiacheng; Huo, XiaoJiao; Jarpe, Matthew B et al. (2018) Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment. Acta Neuropathol Commun 6:103
Meisel, Jane; Zhang, Chao; Neely, Cameron et al. (2018) Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clin Breast Cancer 18:347-352
Williams, Patrick; Basu, Sreyashi; Garcia-Manero, Guillermo et al. (2018) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer :
Koyyalagunta, Dhanalakshmi; Bruera, Eduardo; Engle, Mitchell P et al. (2018) Compliance with Opioid Therapy: Distinguishing Clinical Characteristics and Demographics Among Patients with Cancer Pain. Pain Med 19:1469-1477
Liao, Zhongxing; Lee, J Jack; Komaki, Ritsuko et al. (2018) Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 36:1813-1822
Ma, Junsheng; Hobbs, Brian P; Stingo, Francesco C (2018) Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res 27:2093-2113

Showing the most recent 10 out of 12418 publications